Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.

Molecular neurobiology - 1 May 2019

Esteves Sofia, Oliveira Stéphanie, Duarte-Silva Sara, Cunha-Garcia Daniela, Teixeira-Castro Andreia, Maciel Patrícia

Abstract excerpt

Spinocerebellar ataxias are dominantly inherited neurodegenerative disorders with no disease-modifying treatment. We previously identified the selective serotonin reuptake inhibitor citalopram as a safe and effective drug to be repurposed for Machado-Joseph disease. Pre-symptomatic treatment of transgenic (CMVMJD135) mice strikingly ameliorated mutant ataxin-3 (ATXN3) pathogenesis. Here, we asked whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxin-3
Share to Citalopram
Share to Gait

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Machado-Joseph Disease

Share to Mice, Transgenic

Share to Motor Activity

Share to Neuroprotective Agents

Share to Trinucleotide Repeat Expansion

Source

Identifiers

PMID: 30173407
DOI: 10.1007/s12035-018-1332-1

Genes

ATXN3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.PMID 30173407Read ↗

Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease.Semantic proximity Read ↗

Recent therapeutic prospects for Machado–Joseph diseaseSemantic proximity Read ↗

Pharmacological Therapies for Machado-Joseph Disease.Semantic proximity Read ↗

Spermidine for the treatment of Machado-Joseph disease: induction of autophagy but also apoptosis?Semantic proximity Read ↗

Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.Semantic proximity Read ↗

RNA Interference Mitigates Motor and Neuropathological Deficits in a Cerebellar Mouse Model of Machado-Joseph DiseaseSemantic proximity Read ↗

Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph DiseaseSemantic proximity Read ↗

Caring for Machado-Joseph disease: current understanding and how to help patients.Semantic proximity Read ↗

AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency.Semantic proximity Read ↗

Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado–Joseph diseaseSemantic proximity Read ↗

AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in an Allan-Herndon-Dudley Syndrome mouse modelSemantic proximity Read ↗

Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.